FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Nur für Forschungszwecke. Vollständige Erklärung →

Forschung/Peptide Study Investigates Natural Extracts to Combat Obesity
Zurück zur Forschungsbibliothek

Peptide Study Investigates Natural Extracts to Combat Obesity

May 25, 2026
Share
Emergierende Forschung

Basiert auf emergierender Forschung. Diese Erkenntnisse sind versprechend, aber erfordern weitere Validierung.

Über diese Analyse

Diese Artikel sind eine AI-basierte Zusammenfassung eines kürzlich veröffentlichten Nachrichtenspieles oder einer klinischen Studienanzeige. Sie sind dazu gedacht, einen schnellen und zugänglichen Überblick für die Peptidforschungscommunity zu bieten. Für vollständige Genauigkeit empfehlen wir immer die unten angegebene Quelle zu überprüfen.

Peptide Study Investigates Natural Extracts to Combat Obesity

A new study from the University of Yaounde 1 in Cameroon aims to explore how natural plant extracts might help manage obesity by influencing peptides that regulate appetite and metabolism. Researchers are looking at Cissus quadrangularis and Dichrostachys glomerata extracts as potential tools for boosting glucagon-like peptide-1 (GLP-1) levels, a key hormone involved in glucose regulation and satiety.

Background

Obesity is a growing global health concern, affecting over 2.3 billion people worldwide. The condition often leads to serious health complications such as type 2 diabetes, heart disease, and hypertension. Current treatments for obesity include lifestyle changes, medications, and surgical interventions, but the search continues for more effective and natural options.

Peptides are small proteins that play crucial roles in various biological processes, including appetite control and metabolism regulation. One of these peptides is GLP-1, which helps regulate blood sugar levels by slowing digestion and increasing insulin production. However, GLP-1 can be broken down quickly by the DPP-4 enzyme, reducing its effectiveness.

The study aims to investigate whether extracts from two plants—Cissus quadrangularis (a common medicinal plant) and Dichrostachys glomerata (used in traditional medicine)—can enhance GLP-1 levels while inhibiting DPP-4 activity. This could potentially offer a natural approach to managing obesity through better regulation of appetite and metabolism.

Key Details

The study, which began recruiting participants in 2026, is divided into phases one and two. Phase one focuses on safety assessments and initial dosing evaluations, while phase two will assess the effectiveness of these plant extracts in altering GLP-1 levels and DPP-4 activity in overweight or obese adults.

Participants will receive standardized Cissus quadrangularis extract (CQE), Dichrostachys glomerata extract (DGE), or a placebo. Researchers will monitor changes in body weight, food intake, satiety, as well as GLP-1 levels and DPP-4 activity throughout the trial period.

The study is particularly interesting for peptide researchers who are always on the lookout for new compounds that can modulate biological processes effectively. The use of natural extracts adds a unique dimension to traditional peptide therapies by potentially offering safer alternatives with fewer side effects.

Key Takeaways

  • Natural Compounds: Cissus quadrangularis and Dichrostachys glomerata extracts are being evaluated as potential tools for obesity management.
  • GLP-1 Regulation: The study focuses on enhancing GLP-1 levels to improve satiety and metabolism regulation, reducing appetite and promoting weight loss.
  • DPP-4 Inhibition: By inhibiting the DPP-4 enzyme, these extracts may help maintain higher levels of active GLP-1 in the body.
  • Safety Assessment: Phase one will ensure that the plant extracts are safe for use in humans before moving to efficacy trials.

What This Means

This study is part of a broader trend in peptide research and therapy, where natural compounds are being explored as potential modulators of biological processes. If successful, it could pave the way for new dietary supplements or medications derived from these plants that can complement existing obesity treatment strategies without the side effects often associated with synthetic drugs.

For clinicians and researchers involved in peptide therapy, this study provides valuable insights into how traditional medicine might contribute to modern healthcare solutions. Additionally, regulatory bodies like the FDA will need to consider the implications of approving natural extracts for therapeutic use, ensuring they meet rigorous safety and efficacy standards.

---

Source: ClinicalTrials.gov — Published 2026-05-15

This article is for informational purposes only and does not constitute medical advice.

Bearbeitungsnotiz

Diese Analyse wurde mit AI-Tools generiert und durch den Peptide Contacts-Bearbeiterteam geprüft. Obwohl wir für die Genauigkeit streben, kann AI-generierter Inhalt Fehler oder Lücken enthalten. Wir ermutigen Leser, die ursprüngliche Quelle für vollständige Details, Methoden und Daten.

Peptide Contacts bietet vercurierte Forschungssummarien zur Informationszwecke an. Dieses Inhalte bilden keine medizinische Beratung aus. Stets beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.

Comments

Sign in to join the discussion

Dieser Artikel wurde mit AI generiert und kann ungenaue Informationen enthalten. Er wird zur Informationszwecke bereitgestellt und bildet keine medizinische Beratung aus. Stets überprüfen Sie die Information mit der ursprünglichen Quelle und beraten Sie sich mit einer qualifizierten Gesundheitsversorgerin, bevor Sie irgendeine Gesundheitsentscheidungen treffen.